T1	p 77 106	anemic patients with cancer .
T2	p 222 271	patients with cancer-associated anemia . PATIENTS
T3	p 284 301	Eligible patients
T4	p 571 659	Three hundred sixty-five patients were enrolled . One hundred eighty-three patients were
T5	i 59 73	erythropoietin
T6	i 138 150	epoetin alfa
T7	i 205 217	epoetin alfa
T8	i 372 415	epoetin alfa 40,000 U subcutaneously ( SC )
T9	i 427 471	by either standard weekly epoetin alfa ( 40K
T10	i 491 513	of epoetin alfa ( 120K
T11	i 1544 1565	epoetin alfa 40,000 U
T12	i 1578 1587	120,000 U
T13	i 1751 1763	epoetin alfa
T14	o 757 802	proportion of patients requiring transfusions
T15	o 1170 1261	mean end-of-study Hb levels . Toxicities , including thromboembolism , and overall survival
T16	o 1314 1344	global quality of life ( QOL )
T17	o 1426 1448	global QOL improvement
T18	o 1484 1487	QOL
T19	o 1686 1689	QOL